ADPV vs IVZ

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ADPV as a result. In 59 of 68 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for ADPV just turned positive on October 20, 2026. Looking at past instances where ADPV's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.

Following a +1.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADPV advanced for three days, in 248 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

The Aroon Indicator entered an Uptrend today. In 238 of 278 cases where ADPV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADPV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IVZ's RSI Indicator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 56 cases where IVZ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Moving Average Convergence Divergence (MACD) for IVZ just turned positive on October 28, 2026. Looking at past instances where IVZ's MACD turned positive, the stock continued to rise in 33 of 45 cases over the following month. The odds of a continued upward trend are 73%.

Following a +3.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVZ advanced for three days, in 227 of 334 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

IVZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.

The Aroon Indicator for IVZ entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. IVZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 50 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock slightly better than average.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.271) is normal, around the industry mean (2.397). P/E Ratio (-42.806) is within average values for comparable stocks, (-3.450). Projected Growth (PEG Ratio) (0.901) is also within normal values, averaging (1.319). Dividend Yield (0.030) settles around the average of (0.272) among similar stocks. P/S Ratio (1.981) is also within normal values, averaging (15.798).

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.